Biomarker Lens

Biomarkers · Chemical

PL-7

Understand what PL-7 signals

LOINC codes
45149-2, 56731-3, 56744-6, 56745-3, 63559-9, 69557-7, 82425-0, 88725-7, 88732-3, 88733-1, 88739-8, 93493-5, 94097-3
Commercial laboratory assays
2

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for PL-7

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Extended Myositis Specific Antibody (MSA) Panel

Laboratory
Quest Diagnostics
Test code
10257
Specimen
Serum
Fasting
Not stated
LOINC
45149-2, 56731-3, 56744-6, 56745-3, 63559-9, 69557-7, 82425-0, 88725-7, 88732-3, 88733-1, 88739-8, 93493-5, 94097-3

Laboratory assay overview

The Extended Myositis Specific Antibody (MSA) panel is designed as an aid for the diagnosis of myopathies associated with autoantibody production. These include inflammatory myopathies (polymyositis, anti-synthetase syndrome, dermatomyositis), necrotizing myopathies, including statin associated myopathy, and inclusion body myositis.

View complete laboratory reference notes

See individual tests

Quest Diagnostics test directory, test code 10257

Myositis Specific 11 Antibody Panel

Laboratory
Quest Diagnostics
Test code
94777
Specimen
Serum
Fasting
Not stated
LOINC
45149-2, 56731-3, 56744-6, 56745-3, 63559-9, 69557-7, 82425-0, 88725-7, 88732-3, 88733-1, 88739-8
Turnaround
Set up: Tues-Sat; Report available: 3-5 days

Laboratory assay overview

Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodeling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Jo-1 Ab<11 SI
PL-7 Ab<11 SI
PL-12 Ab<11 SI
EJ Ab<11 SI
OJ Ab<11 SI
SRP Ab<11 SI
Mi-2 Alpha Ab<11 SI
Mi-2 Beta Ab<11 SI
MDA5 Ab<11 SI
TIF1 Gamma Ab<11 SI
NXP-2 Ab<11 SI
View complete laboratory reference notes

Jo-1 Ab <11 SI PL-7 Ab <11 SI PL-12 Ab <11 SI EJ Ab <11 SI OJ Ab <11 SI SRP Ab <11 SI Mi-2 Alpha Ab <11 SI Mi-2 Beta Ab <11 SI MDA5 Ab <11 SI TIF1 Gamma Ab <11 SI NXP-2 Ab <11 SI

Quest Diagnostics test directory, test code 94777

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.